RT Journal Article
SR Electronic
T1 Diverse Functional Autoantibodies in Patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.10.20247205
DO 10.1101/2020.12.10.20247205
A1 Wang, Eric Y.
A1 Mao, Tianyang
A1 Klein, Jon
A1 Dai, Yile
A1 Huck, John D.
A1 Liu, Feimei
A1 Zheng, Neil S.
A1 Zhou, Ting
A1 Israelow, Benjamin
A1 Wong, Patrick
A1 Lucas, Carolina
A1 Silva, Julio
A1 Oh, Ji Eun
A1 Song, Eric
A1 Perotti, Emily S.
A1 Fischer, Suzanne
A1 Campbell, Melissa
A1 Fournier, John B.
A1 Wyllie, Anne L.
A1 Vogels, Chantal B. F.
A1 Ott, Isabel M.
A1 Kalinich, Chaney C.
A1 Petrone, Mary E.
A1 Watkins, Anne E.
A1 ,
A1 Cruz, Charles Dela
A1 Farhadian, Shelli F.
A1 Schulz, Wade L.
A1 Grubaugh, Nathan D.
A1 Ko, Albert I.
A1 Iwasaki, Akiko
A1 Ring, Aaron M.
YR 2020
UL http://medrxiv.org/content/early/2020/12/12/2020.12.10.20247205.abstract
AB COVID-19 manifests with a wide spectrum of clinical phenotypes that are characterized by exaggerated and misdirected host immune responses1–8. While pathological innate immune activation is well documented in severe disease1, the impact of autoantibodies on disease progression is less defined. Here, we used a high-throughput autoantibody discovery technique called Rapid Extracellular Antigen Profiling (REAP) to screen a cohort of 194 SARS-CoV-2 infected COVID-19 patients and healthcare workers for autoantibodies against 2,770 extracellular and secreted proteins (the “exoproteome”). We found that COVID-19 patients exhibit dramatic increases in autoantibody reactivities compared to uninfected controls, with a high prevalence of autoantibodies against immunomodulatory proteins including cytokines, chemokines, complement components, and cell surface proteins. We established that these autoantibodies perturb immune function and impair virological control by inhibiting immunoreceptor signaling and by altering peripheral immune cell composition, and found that murine surrogates of these autoantibodies exacerbate disease severity in a mouse model of SARS-CoV-2 infection. Analysis of autoantibodies against tissue-associated antigens revealed associations with specific clinical characteristics and disease severity. In summary, these findings implicate a pathological role for exoproteome-directed autoantibodies in COVID-19 with diverse impacts on immune functionality and associations with clinical outcomes.Competing Interest StatementA.M.R., E.Y.W., and Y.D. are inventors of a patent describing the REAP technology.Funding StatementThis work was supported by the Mathers Family Foundation (to A.M.R. and A.I.), the Ludwig Family Foundation (to A.M.R. and A.I.), a supplement to the Yale Cancer Center Support Grant 3P30CA016359-40S4 (to A.M.R), the Beatrice Neuwirth Foundation, Yale Schools of Medicine and Public Health and NIAID grant U19 AI08992. IMPACT received support from the Yale COVID-19 Research Resource Fund. A.M.R. is additionally supported by an NIH Director's Early Independence Award (DP5OD023088) and the Robert T. McCluskey Foundation. T.M. is supported by the Yale Interdisciplinary Immunology Training Program T32AI007019. J.K. is supported by the Yale Medical Scientist Training Program T32GM007205. C.B.F.V. is supported by NWO Rubicon (no. 019.181EN.004).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, protocol ID 2000027690).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll non PHI data in the manuscript will be made available upon request.